BioNTech is pivoting from its pandemic vaccine fame to tackle the massive, underserved cancer market—projected to hit $500 billion by 2035. With 25+ advanced oncology trials underway, including a breakthrough bispecific antibody, pumitamig, in partnership with Bristol Myers Squibb, the company aims to disrupt cancer treatment and generate billions annually. While their pipeline is promising and spans beyond cancer—including vaccines for TB and HIV—their stock faces scrutiny due to falling sales and lack of consistent profitability, making investors nervous about clinical or regulatory setbacks.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
